media – Page 127 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

HS and NICE announce plan to adopt innovative medical technologies for patients

The proposals will help MedTech developers access NHS funding to fast-track products NHS England and the National Institute for Health and Care Excellence (NICE) have announced a new plan to adopt innovative medical technologies to provide faster access to NICE-recommended products and improve patient outcomes. The proposals set out a route for MedTech developers to access NHS funding to fast-track clinically and cost-effective products to be used by NHS England. Developed by NHS England and NICE with input from the Department of Health and Social Care, as well as other partners including the Office for Life Science and the Medicines and Healthcare products Regulatory Agency, the new plans will also support MedTech innovators and suppliers with automatic funding to support routine commissioning for technologies that meet the required criteria. NHS England’s interim medical director for transformation, Dr Vin Diwaker, said: “Medical technology plays a vital role in the nation’s health ...
- Source: drugdu
- 85
- June 1, 2024
Fresenius Medical Care plans layoffs ahead of California plant closure

Dive Brief Fresenius Medical Care will lay off more than 300 people as part of a planned closure of a manufacturing plant in Concord, California. The cuts will begin in August and continue through mid-2025, according to a Worker Adjustment and Retraining Notification (WARN) filing with California. CEO Helen Giza told investors on a May 7 call that the company is moving production from California to Mexico to reduce costs and improve margins. Dive Insight Fresenius Medical Care, which makes dialysis equipment and operates dialysis centers around the world, is looking to tighten spending in its first year as an independent company. The firm was separated from parent company Fresenius in November, with Fresenius keeping a 32% stake. Giza told investors that “several initiatives are underway” to optimize Fresenius Medical Care’s manufacturing footprint and supply chain. The company will move all dialysis manufacturing operations from Concord, California, to a facility ...
- Source: drugdu
- 118
- June 1, 2024
New Assay Detects Heart Failure Biomarker in Less than 11 Minutes

According to the Heart Failure Society of America, nearly 6.5 million Americans over the age of 20 suffer from heart failure, which accounts for about 8.5% of all heart disease deaths in the United States. A new assay now aids in diagnosing individuals who are suspected of having acute heart failure in emergency departments, as well as in evaluating the severity and risk stratification of patients with heart failure and acute coronary syndrome. The Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay from Beckman Coulter (Brea, CA, USA) measures the levels of N-terminal pro B-type natriuretic peptide in serum or plasma that is released in the heart. Elevated levels of these peptides may indicate heart failure. As per the latest heart failure guidelines issued by the American College of Cardiology and the American Heart Association, the Access NT-proBNP assay includes age-based cutoffs to aid in the accurate diagnosis of heart ...
- Source: drugdu
- 111
- June 1, 2024
Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury

Traumatic brain injury (TBI) occurs when external mechanical energy is transferred to brain tissue, causing cellular damage, dysfunction, and dysregulation. It is a significant public health issue, being a leading cause of death and disability globally, with approximately 69 million people affected each year. For clinicians assessing these patients, it is crucial to quickly ascertain the presence or absence of potentially life-threatening hemorrhages and neurological complications. TBI severity is evaluated using the Glasgow Coma Scale (GCS) and categorized as mild, moderate, or severe. Mild traumatic brain injuries (mTBI) are the most common, comprising 70-90% of all TBI cases, and they are the least likely to lead to acute medical emergencies. It is noted that about 90% of mTBI patients who receive computed tomography (CT) scans show no abnormal findings. Despite this, an estimated 82% of all TBI patients are scanned, many of which could potentially be unnecessary. These scans not ...
- Source: drugdu
- 95
- May 31, 2024
New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant

Bone marrow transplant, also referred to as hematopoietic cell transplantation (HCT), serves as a critical treatment for children with leukemia, bone marrow failure, and various genetic disorders, including inborn immunodeficiencies and sickle-cell disease. However, the procedure is intense, involving high doses of chemotherapy to eradicate diseased cells in the bone marrow. This treatment suppresses the immune system to allow healthy stem cells to grow, which are then transplanted into the patients. Due to this immune suppression, patients become highly susceptible to viruses, bacteria, and other pathogens during the critical phase when their immune system is “rebooting.” Lung infections are especially prevalent among these patients, affecting up to 40% of pediatric HCT recipients. When these infections require ventilator support, the mortality rate can be as high as 50%. Identifying the specific pathogens involved is challenging because doctors using conventional diagnostic tests may not be able to target the correct ones, given ...
- Source: drugdu
- 151
- May 31, 2024
J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition

Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month. By Frank Vinluan Johnson & Johnson is building up its immunology pipeline, striking a $1.25 billion deal for a bispecific antibody in development for atopic dermatitis — its second acquisition agreement in the indication in the past two weeks. The deal announced Tuesday will bring J&J a Numab Therapeutics drug codenamed NM26. The pharmaceutical giant is acquiring global rights to the experimental treatment, which is ready to enter Phase 2 testing. Atopic dermatitis, also known as eczema, is the most common inflammatory skin disease. While the disorder typically presents as red and itchy skin, it stems from multiple pathways that vary from one group of patients to another. NM26 is a bispecific antibody designed to address two of ...
- Source: drugdu
- 117
- May 31, 2024
Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis

Don Tracy, Associate Editor The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion. Image Credit: Adobe Stock Images/Ityuan Johnson & Johnson (J&J) announced that it has agreed to terms with Numab Therapeutics to acquire its wholly owned subsidiary for the global rights to NM26, an investigational bispecific antibody currently in Phase II of development for the treatment of atopic dermatitis (AD). Under terms of the deal, J&J will pay Numab around $1.25 billion in an all-cash transaction. According to the company, the transaction is expected to close later this year, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of customary closing conditions. NM26 targets two established pathways, interleukin (IL)-4Rα and IL-31, in AD. According to investigators, this works by targeting IL-4Rα, which is responsible for Th2-mediated skin inflammation, and IL-31, which triggers skin itch and exacerbates AD. Additionally, NM26 has demonstrated ...
- Source: drugdu
- 109
- May 31, 2024
Entod Pharma launches Vitamin D3 eye drops

Entod Pharmaceuticals has launched Vitamin D3 enriched lubricating eye drops. These novel formulations aim to benefit ocular health, providing targeted relief for individuals suffering from dry eyes. Vitamin D3 has now been incorporated into some of Entod’s selected lubricant eye drop brands that are currently prescribed by eye doctors for dry eyes. Dry eye syndrome is a prevalent condition characterised by discomfort, irritation, and even vision impairment. The main causes of dry eyes are environmental factors, Vitamin deficiencies, Poor blinking habits, Contact lenses, Digital devices, Smoking, Refractive surgeries and more. Commenting on the launch, Nikkhil K Masurkar, CEO, Entod said, “ Adding Vitamin D3 to routine dry eye treatment improves ocular surface hemostasis parameters, results in better tear stability, improves tear osmolarity, and helps modulate corneal wound healing. Vitamin D3 enriched lubricating eye drops would only be available through health care professional prescriptions.” Emphasising the significance of Vitamin D on ...
- Source: drugdu
- 86
- May 31, 2024
Glenmark creates mass awareness around Hypertension

Glenmark Pharmaceuticals, marked the month of May as the ‘Hypertension Awareness Month’ by reportedly partnering with more than 1000 healthcare professionals (HCPs) from 250+ cities and towns across the country, and organised 400+ public awareness rallies and screening camps to create mass awareness around Hypertension (High Blood Pressure). The rallies consisted of general informative sessions led by HCPs, who provided detailed insights on the signs, symptoms, and preventive measures related to Hypertension. Subsequently, blood pressure screening camps were set up to offer the general public an opportunity to assess their blood pressure levels. Reportedly, as a result of this initiative, Glenmark successfully reached out to 6 million adults, effectively raising awareness about the disease. Hypertension, a prevalent cardiovascular disease (CVD) risk factor, affects approximately 35.5 per cent of adults in India. Alarmingly, CVD is the leading cause of death in the country, responsible for almost one-fourth of all mortality cases. ...
- Source: drugdu
- 89
- May 31, 2024
FDA grants priority review to Genentech’s Inavolisib

Genentech, a member of the Roche Group, announced that the USFDA has accepted the company’s new drug application and granted priority review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. The priority review is based on the positive Phase III INAVO120 results, which showed the inavolisib-based regimen more than doubled progression-free survival, reducing the risk of disease worsening or death by 57 per cent compared to palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43, 95 per cent CI: 0.32-0.59, p<0.0001) in the first-line setting. Overall survival (OS) data were immature at the time of primary analysis, but a clear positive trend was observed ...
- Source: drugdu
- 90
- May 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.